This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward-looking statements involve risk and uncertainty. Forward-looking statements represent the company's judgment regarding future events, and are based on currently available information. Consequently the company cannot guarantee their accuracy and their completeness and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of. For additional information concerning these and other important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the ‘Autorité des Marchés Financiers’.
Cegedim profile

Global technology and services company specializing in healthcare

Global leader driven by innovation

Customers

Pharmaceutical and Life-Sciences companies worldwide

Doctors, Pharmacists and Paramedics in Europe & USA

Healthcare insurance in France

Revenue

as of 12/31/2010

Key figures

as of 12/31/2010

2010 revenue

€927M

+ 6.0%

Recurring business

65%
Key figures

- Revenues: €459m (+2.2%)
- Recurring EBIT: €41m (-18.2%)
- Net Profit Group Share: €17.1m (-13.9%)
- Earnings per Share: €1.2 (-13.9%)
Cegedim activities focus on healthcare

- **CRM & Strategic Data**
  - For Pharmaceutical Companies
  - Databases: Onekey
  - CRM tools
  - Market Research
  - Strategic Data
  - 80 countries Worldwide Leader

- **Healthcare Professionals**
  - For Doctors, Pharmacists, Paramedics
  - Physicians
  - Paramedics
  - Pharmacists
  - Financial Leasing
  - Software, Databases, Services
  - Cegelease
  - Europe and USA European Leader

- **Insurance & Services**
  - For Insurers and Health Mutuels
  - IT for healthcare insurers
  - Flows and electronic payment
  - Services
  - France Leader in France

---

This document should not be distributed without Cegedim authorization — Copyright 2011
No direct competitor covers the entire value chain

<table>
<thead>
<tr>
<th>Healthcare Insurance Software</th>
<th>Flow</th>
<th>Leasing</th>
<th>Pharmacists software</th>
<th>Doctor's software</th>
<th>Compliance</th>
<th>Market research</th>
<th>Strategic Data</th>
<th>Databases</th>
<th>CRM SaaS</th>
<th>CRM licence</th>
<th>Integration</th>
<th>Services</th>
<th>Siebel</th>
<th>VoD - Veeva Systems</th>
<th>Local Players</th>
<th>IMS</th>
<th>Synovate</th>
<th>inVentiv</th>
<th>Compugroup EMIS</th>
<th>Pharmagist</th>
<th>GE Capital</th>
<th>B-Process</th>
<th>Accenture</th>
<th>IBM</th>
</tr>
</thead>
</table>
Snapshot of Cegedim strenght

- **Experienced Team**
  - Stable management
  - Group of entrepreneurs
  - Chairman is the founder

- **Strong Entry Barriers**
  - Unique global healthcare professionals data
  - Long clients relation
  - Largest CRM hosting structure

- **Stable Shareholder Base**
  - Majority family shareholding
  - Strong long-term shareholding
  - Large free-float

- **Strong Spirit of Innovation**
  - R&D around 8% of revenue

- **Rich History of Innovations**
  - 40 years history

- **Strong Spirit of Innovation**
  - No direct competitors in all services

- **Adaptability**
  - Flexibility to adapt to market's expectations & new needs

- **Solid Financial Structure**
  - Strong balance sheet
  - High recurring revenue

- **Promising Acquisitions**
  - SK&A: best US healthcare professional database
  - Pulse Inc.: access to US EHR exponential market
CRM & Strategic Data Snapshot

CRM & STRATEGIC DATA AS OF JUNE 30, 2011

KEY FIGURES

% REVENUE
54%

% EBIT
17%

MARGIN
2.8%

REVENUE BREAKDOWN

- EMEA ex.France: 10%
- France: 23%
- Americas: 35%
- APAC: 32%

In millions of euros

CLIENTS/OFFERS

CLIENTS:
- Pharma.
- Companies
- Governments
- Universities

OFFERS:
- Solutions: Global CRM, Reporting
- Market research
- Databases

HEALTHCARE PROFESSIONALS

INSURANCE & SERVICES

Healthcare Professionals
Insurance & Services
Finance
Highlights

→ Market Trend

- Industry consolidation
- Government cost pressure
- Healthcare reform
- Generic competition
- Trend in the number of Med. Reps.

<table>
<thead>
<tr>
<th>Country</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2015e</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mature</td>
<td>325,000</td>
<td>316,000</td>
<td>301,000</td>
<td>210,000</td>
</tr>
<tr>
<td>Emerging</td>
<td>179,000</td>
<td>194,000</td>
<td>219,000</td>
<td>305,000</td>
</tr>
<tr>
<td>Other</td>
<td>7,000</td>
<td>8,000</td>
<td>10,000</td>
<td>15,000</td>
</tr>
<tr>
<td>Total</td>
<td>511,000</td>
<td>518,000</td>
<td>530,000</td>
<td>530,000</td>
</tr>
</tbody>
</table>

→ Cegedim

- Innovation
  - 8% of group revenue
  - 16% of workforce
  - Recognize by the industry
- Great success for new products
  - AggregateSpend360™
  - Organization Manager™
  - OneKey
- Robust and steady growth in emerging countries
  - 11% of Group revenue and L-f-L growth of 16%
- Return to normal in the roll-out of CRM offering
  - Great commercial success
    - Setting up a saving plan

→ Innovation key point for success

→ The life-science industry is growing and changing
An Award Winning Company

IDC Pharmaceutical SFA MarketScape

What IDC Says About Cegedim

“Cegedim’s application ranks among the best available for breadth of functionality, user interface and functional flexibility…”

“Cegedim offers a complete line of deployment options (on-premise, hosted, and multitenant and dedicated SaaS) … ”

“Cegedim has a large number of strong customer references.”

Frost & Sullivan Mobile SFA Competitive Strategy Innovation Award

What Frost Said About Cegedim

“Cegedim innovates against it’s competitors on a number of levels.”

“Cegedim’s mobile product portfolio is competitively unique.”
Key Wins/Renewals 1st Half 2011

Top 10 Biopharm C\textsuperscript{\textregistered}y
Global
MI SaaS in Emerging markets

Leading Biopharm C\textsuperscript{\textregistered}y
EU
Migrate to MI for IPad in 15 countries

3 Emerging Biopharma C\textsuperscript{\textregistered}ies
US
2 Cy selected MI for IPad, 1 Cy upgrade to MI

Top 10 Pharmaceutical C\textsuperscript{\textregistered}y
Germany
Major Analytics project

Various Large, Mid-Tier and Emerging Pharma C\textsuperscript{\textregistered}ies
Global
OneKey data services

Leading Specialty Healthcare C\textsuperscript{\textregistered}y
US
Expands to Mobile Intelligence, MI for iPad, help desk and hardware management services

Large, Medium and Emerging Biopharma C\textsuperscript{\textregistered}ies
US
12 deals on AggregateSpend360 SaaS with a majority including OneKey & Nucleus360

Forest Labs
US
Full service management contract

Top 25 Pharmaceutical C\textsuperscript{\textregistered}ies
Russia
Mobile Intelligence & OneKey data services

Top 15 Bioparma. C\textsuperscript{\textregistered}
Global
OneKey data in 33 countries

Top 10 Biopharmaceutical C\textsuperscript{\textregistered}y
Japan
Upgrade to Mobile Intelligence

2 Top 25 Pharmaceutical C\textsuperscript{\textregistered}ies
Russia
Mobile Intelligence & OneKey data services

Organization Manager SaaS in 70 countries

Top 25 Pharma. C\textsuperscript{\textregistered}
Mobile Enterprise edition, OneKey and Market Access

2 Top 20 Biopharmaceutical C\textsuperscript{\textregistered}ies
Global
Migrate to Mobile Intelligence SaaS in 10 and 8 countries respectively

U.S. Department of Healthcare & Human Services

This document should not be distributed without Cegedim authorization – Copyright 2011
HEALTHCARE PROFESSIONALS AS OF JUNE 30, 2011

**CLIENTS/OFFERS**
- Physicians
- Pharmacists
- Paramedics
- Revenue Cycle Management
- Financial Leasing
- E-HR, E-Prescription, Medication data

**OFFERS:**

**KEY FIGURES**
- % REVENUE: 31%
- % EBIT: 59%
- MARGIN: 17.4%

**REVENUE BREAKDOWN**
- 4% EMEA ex.France
- 24% France
- 72% Americas
- APAC

In millions of euros
Expertise

CHS OFFERS

PHARMACISTS
+ PRODUCTS
  > Practice Management Software
  > Medication Database
  > E-Prescription
  > Revenue Cycle Management
  > Electronic Healthcare Record

PHYSICIANS
+ SERVICES

CEGELEASE RNP OFFERS

> Financial Leasing
> Point of sales advertising
Global presence

Cegedim Healthcare Software

**Doctors**
115,000 work stations
- France #1
- R-U #2
- Spain #1
- Belgium #2
- Italy #1
- USA #2

**Pharmacists**
78,000 work stations
- France #1
- U-K #2
- Tunisia #1
- Romania #2

**Paramedics**
30,000 work stations
- France #1

Cegelease

65% of pharmacists
- France #1

RNP

- France #1
Highlights

→ Cegedim Healthcare Software

→ Gouvernements initiatives
  - Governments across the globe recognize the importance of integrated healthcare systems
  - Healthcare modernization is one of the priority areas of fund allocation in all recovery programs

→ Rising healthcare costs triggers quest for efficiency
  - Healthcare IT tool to help control costs in the medium term: improved coordination, traceability, paperless environment, staff shortage, patient safety, and pay-of-performance systems
  - Significant growth potential in EMEA and US where computerization of healthcare value chain continues

→ Increased GP awareness

→ Principally UK and France drive revenue and margin increase
→ Exposure to favorable reforms in France and the UK
→ The excellent prospects for growth in managing electronic records (EHR) in the US are beginning to materialize

→ Cegelease
  - Drop of around 13% in Cegelease’s revenue as expected
  - Significant drop in margin

→ RNP
  - Shift to digital
Insurance & Services Snapshot

INSURANCE & SERVICES AS OF JUNE 30, 2011

CLIENTS/OFFERS

OFFERS:
- Insurers
- Health Mutuals
- Software
- Flow and Electronic Payment
- Services

KEY FIGURES

% REVENUE
- 15%

% EBIT
- 24%

MARGIN
- 14.3%

REVENUE BREAKDOWN

- EMEA ex.France: 1%
- France: 99%
- Americas: 0%
- APAC: 0%

In millions of euros
Expertise

IT for healthcare insurers
- Leader in France
- Development in Morocco and Mali
- More than 30 million policy holders in France

Flows and electronic payments
- Leader in France
- Management of direct payment by insurers
- More than 250 million EDI flows per year

Services
- Management Services
- Electronic Data Interchange (EDI)
- Outsourced Payroll and HR Management
Industry in turmoil with the online services

Cegedim Activ hampered by a tough year-on-year comparison

Rebound expected in the second half-year 2011

Strong increase in flow management activity

Margin improvement

Cegedim SRH

Robust trend in the sales of services associated with outsourcing payroll

Cegedim e-business

Success in dematerialization offer

Successful integration of Deskom
02  Finance
HY’11 financial snapshot

**Revenue**
Acquisitions positive effect

- Revenue: €448.8M (HY 2010) to €458.6M (HY 2011) (+2.2%)

**EBIT**
Impact of implementation issue

- EBIT: €45.2M (HY 2010) to €38.7M (HY 2011) (-14.4%)

**Consolidated net earnings group share**
Strong tax rate decrease

- Net earnings: €19.8M (HY 2010) to €17.1M (HY 2011) (-13.9%)

**Shareholders equity**
Currency assessment

- Shareholders equity: €480M (2010) to €449M (HY 2011) (-6.5%)

**Net financial debt**
Cash decrease

- Net financial debt: €162M (2010) to €475M (HY 2011) (+3.0%)

**Gearing**

- Gearing: x1.0 (2010) to x1.1 (HY 2011)
**Consolidated revenue in line with targets**

### HY’11 sector development

<table>
<thead>
<tr>
<th>In millions of euros</th>
<th>HY 2011</th>
<th>HY 2010</th>
<th>Organic</th>
<th>Structure</th>
<th>Currency</th>
<th>Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM &amp; Strategic data</td>
<td>249.2</td>
<td>249.1</td>
<td>+0.3%</td>
<td>+0.3%</td>
<td>-0.6%</td>
<td>+0.0%</td>
</tr>
<tr>
<td>Healthcare professionals</td>
<td>140.2</td>
<td>138.7</td>
<td>-3.3%</td>
<td>4.3%</td>
<td>+0.1%</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Insurance &amp; Services</td>
<td>69.1</td>
<td>61.0</td>
<td>+0.8%</td>
<td>+12.5%</td>
<td>+0.1%</td>
<td>+13.4%</td>
</tr>
<tr>
<td><strong>Cegedim</strong></td>
<td>458.6</td>
<td>448.8</td>
<td>-0.7%</td>
<td>+3.2%</td>
<td>-0.3%</td>
<td>+2.2%</td>
</tr>
</tbody>
</table>

*Reported growth excluding currency impacts

### 2011 organic revenue growth versus same period of 2010

<table>
<thead>
<tr>
<th>Q1 2011</th>
<th>Q2 2011</th>
<th>HY 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM et données stratégiques</td>
<td>-0.8%</td>
<td>+1.3%</td>
</tr>
<tr>
<td>Professionnels de santé</td>
<td>-3.0%</td>
<td>-3.5%</td>
</tr>
<tr>
<td>Assurances et services</td>
<td>-0.4%</td>
<td>+1.8%</td>
</tr>
<tr>
<td><strong>Cegedim</strong></td>
<td>-1.4%</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
Well-balanced and diversified revenue mix

Revenue breakdown by

Highly diversified operations

Low customer concentration as of December 2010

- First client: 5% of Group revenue
- Top 5 client: 15% of Group revenue
- Top 10 client: 22% of Group revenue
### HY’11 summarized income statement

<table>
<thead>
<tr>
<th>in € millions</th>
<th>HY’11</th>
<th>HY’10</th>
<th>Δ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>458.6</td>
<td>448.8</td>
<td>+2.2%</td>
</tr>
<tr>
<td>Capitalized production</td>
<td>22.5</td>
<td>15.2</td>
<td>+48.4%</td>
</tr>
<tr>
<td>Purchases consumed</td>
<td>-49.0</td>
<td>-48.6</td>
<td>+0.8%</td>
</tr>
<tr>
<td>External expenses</td>
<td>-121.6</td>
<td>-110.2</td>
<td>+10.3%</td>
</tr>
<tr>
<td>Taxes</td>
<td>-7.5</td>
<td>-7.1</td>
<td>+5.5%</td>
</tr>
<tr>
<td>Payroll costs</td>
<td>-225.8</td>
<td>-214.0</td>
<td>+5.5%</td>
</tr>
<tr>
<td>Depreciation expenses</td>
<td>-34.0</td>
<td>-33.5</td>
<td>+1.6%</td>
</tr>
<tr>
<td>Provision expenses and write-backs</td>
<td>-2.0</td>
<td>-0.1</td>
<td>n.s.</td>
</tr>
<tr>
<td>Other operating income and expenses</td>
<td>0.1</td>
<td>0.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>Recurring EBIT</td>
<td>41.4</td>
<td>50.6</td>
<td>-18.2%</td>
</tr>
<tr>
<td>Non-current operating income and expenses</td>
<td>-2.7</td>
<td>-5.4</td>
<td>-49.7%</td>
</tr>
<tr>
<td>EBIT</td>
<td>38.7</td>
<td>45.2</td>
<td>-14.4%</td>
</tr>
</tbody>
</table>

**Investment in Innovation**

**Detached personnel**

+1.7% excl. acquisition

**Sharp drop in restructuring costs**
Recurring EBITDA and EBIT per sector

### EBITDA from continuing operations

<table>
<thead>
<tr>
<th></th>
<th>HY'11</th>
<th>HY'10</th>
<th>HY'11</th>
<th>HY'10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>in millions of €</td>
<td>in %</td>
<td>in millions of €</td>
<td>in %</td>
</tr>
<tr>
<td>CRM &amp; Strategic data</td>
<td>20.4</td>
<td>31.3</td>
<td>8.2%</td>
<td>12.6%</td>
</tr>
<tr>
<td>Healthcare professionals</td>
<td>40.0</td>
<td>39.9</td>
<td>28.5%</td>
<td>28.8%</td>
</tr>
<tr>
<td>Insurance &amp; Services</td>
<td>15.1</td>
<td>13.0</td>
<td>21.8%</td>
<td>21.2%</td>
</tr>
<tr>
<td><strong>Cegedim</strong></td>
<td><strong>75.4</strong></td>
<td><strong>84.1</strong></td>
<td><strong>16.4%</strong></td>
<td><strong>18.7%</strong></td>
</tr>
</tbody>
</table>

*Robust margin*

### EBIT from continuing operations

<table>
<thead>
<tr>
<th></th>
<th>HY'11</th>
<th>HY'10</th>
<th>HY'11</th>
<th>HY'10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>in millions of €</td>
<td>in %</td>
<td>in millions of €</td>
<td>in %</td>
</tr>
<tr>
<td>CRM &amp; Strategic data</td>
<td>7.1</td>
<td>18.3</td>
<td>2.8%</td>
<td>7.3%</td>
</tr>
<tr>
<td>Healthcare professionals</td>
<td>24.5</td>
<td>23.8</td>
<td>17.4%</td>
<td>17.2%</td>
</tr>
<tr>
<td>Insurance &amp; Services</td>
<td>9.9</td>
<td>8.5</td>
<td>14.3%</td>
<td>14.0%</td>
</tr>
<tr>
<td><strong>Cegedim</strong></td>
<td><strong>41.4</strong></td>
<td><strong>50.6</strong></td>
<td><strong>9.0%</strong></td>
<td><strong>11.3%</strong></td>
</tr>
</tbody>
</table>

*Margin improvement*
**Change in net earnings**

### P&L part 2

<table>
<thead>
<tr>
<th>in € millions</th>
<th>HY'11</th>
<th>HY'10</th>
<th>Δ</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBIT</td>
<td>38.7</td>
<td>45.2</td>
<td>-14.4%</td>
</tr>
<tr>
<td>Net cost of financial debt</td>
<td>-21.0</td>
<td>-21.6</td>
<td>-2.5%</td>
</tr>
<tr>
<td>Income taxes</td>
<td>-5.0</td>
<td>-16.1</td>
<td>-68.8%</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>4.1</td>
<td>12.1</td>
<td>-66.3%</td>
</tr>
<tr>
<td>Tax expenses</td>
<td>-1.0</td>
<td>-4.1</td>
<td>-76.0%</td>
</tr>
<tr>
<td>Share of profit for the period of EMC</td>
<td>0.5</td>
<td>0.4</td>
<td>+22.7%</td>
</tr>
<tr>
<td>Consolidated net profit</td>
<td>17.1</td>
<td>19.9</td>
<td>-13.9%</td>
</tr>
<tr>
<td>Consolidated net profit Group share</td>
<td>17.1</td>
<td>19.8</td>
<td>-13.9%</td>
</tr>
<tr>
<td>Minority interests</td>
<td>0.1</td>
<td>0.1</td>
<td>-11.9%</td>
</tr>
<tr>
<td>Average number of shares&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>13,964,415</td>
<td>13,963,775</td>
<td>n.s.</td>
</tr>
<tr>
<td>Earnings per share - euro</td>
<td>1.2</td>
<td>1.4</td>
<td>-13.9%</td>
</tr>
</tbody>
</table>

<sup>(1)</sup> excluding treasury stock  
<sup>(2)</sup> restated in 2010 ofr the Dendrite trademark waiver

### Net cost of financial debt

<table>
<thead>
<tr>
<th>in € millions</th>
<th>HY'11</th>
<th>HY'10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interests paid on financial debt</td>
<td>-16.3</td>
<td>-10.9</td>
</tr>
<tr>
<td>Valuation of financial instruments</td>
<td>-3.9</td>
<td>-3.0</td>
</tr>
<tr>
<td>Other financial income and expenses</td>
<td>-0.8</td>
<td>-7.7</td>
</tr>
<tr>
<td>Cost Of Net Financial Debt</td>
<td>-21.0</td>
<td>-21.6</td>
</tr>
</tbody>
</table>

### Change in tax rate<sup>(2)</sup>

[Graph showing changes in tax rate from Dec-07 to Jun-11]
HY’11 Summarized balance sheet
New €280m credit facility

Debt structure
- €80m Undrawn RCF
- €200m Term loan
- €300m Bond
- €45m Subordinated debt
- Others €3.4m

Hedging
- 86% Hedged or fix rate
- 14% Floating rate

Currency
- 100% EUR

Debt repayment
- Maturity extension: 66% of total debt has more than 4 years maturity

Compliance with covenants

Leverage(1) ratio
- Jun-10: 2.3
- Dec-10: 2.4
- Jun-11: 2.6
- Jul-12: 3.0

Coverage(1) ratio
- Jun-10: 7.3
- Dec-10: 6.4
- Jun-11: 5.1
- Jul-12: 4.5

Gearing
- Jun-10: 0.9
- Dec-10: 1.0
- Jun-11: 1.1
- Jul-12: 1.1

(1) As indicated in the bond and bank prospectus
A cash flow-generating model

Operating cash flow before net financial debt expense and taxes in € millions

<table>
<thead>
<tr>
<th>Year</th>
<th>Cash Flow</th>
<th>Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>€91m</td>
<td>17%</td>
</tr>
<tr>
<td>2007</td>
<td>€131m</td>
<td>17%</td>
</tr>
<tr>
<td>2008</td>
<td>€155m</td>
<td>18%</td>
</tr>
<tr>
<td>2009</td>
<td>€171m</td>
<td>20%</td>
</tr>
<tr>
<td>2010</td>
<td>€161m</td>
<td>17%</td>
</tr>
<tr>
<td>2011</td>
<td>€72m</td>
<td>16%</td>
</tr>
</tbody>
</table>

Cash flow margin
Cash flow in € millions

2010 Cash

HY’11 Cash

*Acquisitions net from disposal and net of cash from acquired companies
Cegedim is confident in its future growth potential based on:

- Robust sales momentum, signing a significantly higher number of contracts than last year in part due to the return to normal in the roll-out of CRM offerings

- Potential from emerging countries

- R&D efforts

- The surge in the medical computerization of healthcare professionals around the world

- The online personal insurance services revolution in France

- The global trend in dematerialization
Higher year-end seasonal effect

52% of EBIT generated in second half year

- Traditionally higher sales of software at the end of the year
- Spending of remaining operating budget
- More use of data and market research in Q4 due to reorganization of sales forces, organization of new campaign, annual reporting …
2011 Financial outlook
As of September 2011

→ More cautious about year-end target
  - Growing uncertainty in France and the USA with respect to the marketing strategies of pharmaceutical companies.
  - Economic conditions in general

→ Rigorous cost management relative to expected revenue trends

→ Acquisitions:
  - Estimated budget for 2011 acquisitions: €10m

(1) These projections are as publicly disclosed on August 2011. The fact that Cegedim include these projections in this presentation should not be taken to mean that these amounts continue to be our projections as of any subsequent date.
Strong and stable shareholder base

Shareholder base as of end of June 2011

<table>
<thead>
<tr>
<th>Economic Interest</th>
<th>Voting Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>A FCB</td>
<td>A FCB</td>
</tr>
<tr>
<td>52.51%</td>
<td>64.88%</td>
</tr>
<tr>
<td>B FSI</td>
<td>B FSI</td>
</tr>
<tr>
<td>15.02%</td>
<td>11.16%</td>
</tr>
<tr>
<td>C Cegedim</td>
<td>C Cegedim</td>
</tr>
<tr>
<td>0.32%</td>
<td>0.0%</td>
</tr>
<tr>
<td>D Free Float including</td>
<td>D Free Float including</td>
</tr>
<tr>
<td>Alliance Healthcare France</td>
<td>Alliance Healthcare France</td>
</tr>
<tr>
<td>32.15%</td>
<td>23.95%</td>
</tr>
</tbody>
</table>

Board of directors

- Jean-Claude Labrune: Chairman of the Board
- Laurent Labrune
- Audie Labrune
- Jean-Louis Mery
- Pierre Marucchi: Appointed by the FSI
- Jacques-Henri David: Representative of FCB
- Nicolas Manardo: Appointed by the FSI
- Philippe Alaterre: Representative of GERS
- Anthony Roberts: Representative of Alliance Healthcare France
- Jean-Pierre Cassan: Independent board member in the sense of the AFEP-MEDEF code

Corporate governance

- Compliance with the recommendation of the AFEP-MEDEF code
- Creation of Audit, Strategy, Nomination and Compensation committees
Q3’11 Revenue
November 9

Share ID

- Quotation: NYSE Euronext Paris - compartmont B
- IPO date: April 1995
- ISIN Code: FR0000053506
- Code: CGDM.PA (Reuters), CGM (Bloomberg)
- Closing Data: December 31st
- Price at IPO: 9.52 euros
- Number of shares as of 06/30/2011: 13,997,173
- Market capitalization as of 06/30/2011: €544m

Adjusted stock price (as of 06/30/2011)

 Analyst coverage

Bond
Société Générale: Juliano Hiroshi Torii

Equity
CA Cheuvreux: Michael Beucher
CM-CIC securities: Jean-Pascal Brivady
Gilbert Dupont: Guillaume Cuvillier
Natixis Securities: Thomas Le Quang
Oddo & Cie: Xavier-Emmanuel Pingault
Société Générale: Patrick Jousseame
We welcome your questions and comments

Jan Eryk UMIASTOWSKI
Chief Investment Officer
Head of Investor Relations

investor.relations@cegedim.com
www.cegedim.com/finance

TEL: +33 (0) 1 49 09 33 36